Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Intraocular inflammation measured by anterior chamber cell and flare 1 week · people who received phacoemulsification
1 finding from 1 review
Intraocular inflammation measured by proportion of participants with corneal edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs showed no clear difference in intraocular inflammation measured by proportion of participants with… compared with corticosteroids (low certainty).
1 finding from 1 review
Proportion of participants with best‐corrected visual acuity of 20/40 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with cystoid macular edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs may leads to lower proportion of participants with cystoid macular edema 1 week compared with corticosteroids (low certainty).
1 finding from 1 review
Time to cessation of treatment · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with acute asthma
ICS showed no clear difference in hospital admission compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
Etanercept showed no clear difference in disease‐specific mortality (time to compared with corticosteroids (low certainty).
1 finding from 1 review